Molecure S.A. (MOC.WA)
PLN 8.5
(0.0%)
PLN 8.5
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -22.1 Million PLN | -30.12% |
| 2022 | -16.98 Million PLN | -23.42% |
| 2021 | -13.76 Million PLN | -118.68% |
| 2020 | 73.7 Million PLN | 1627.07% |
| 2019 | -4.82 Million PLN | 5.74% |
| 2018 | -5.12 Million PLN | -98.77% |
| 2017 | -2.57 Million PLN | -2.05% |
| 2016 | -2.52 Million PLN | -218.16% |
| 2015 | -793.45 Thousand PLN | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -6.43 Million PLN | 19.52% |
| 2024 Q2 | -7.99 Million PLN | -12.97% |
| 2024 Q1 | -7.07 Million PLN | 0.16% |
| 2023 Q2 | -5.63 Million PLN | -32.62% |
| 2023 FY | -22.1 Million PLN | -30.12% |
| 2023 Q3 | -5.14 Million PLN | 8.69% |
| 2023 Q4 | -7.08 Million PLN | -37.83% |
| 2023 Q1 | -4.24 Million PLN | 34.58% |
| 2022 Q2 | -4.14 Million PLN | -27.11% |
| 2022 Q4 | -6.48 Million PLN | -110.22% |
| 2022 FY | -16.98 Million PLN | -23.42% |
| 2022 Q1 | -3.26 Million PLN | 52.1% |
| 2022 Q3 | -3.08 Million PLN | 25.58% |
| 2021 Q4 | -6.81 Million PLN | -253.99% |
| 2021 FY | -13.76 Million PLN | -118.68% |
| 2021 Q3 | -1.92 Million PLN | 27.9% |
| 2021 Q2 | -2.66 Million PLN | -13.11% |
| 2021 Q1 | -2.35 Million PLN | -103.11% |
| 2020 Q2 | -512.53 Thousand PLN | 45.29% |
| 2020 Q3 | -765.06 Thousand PLN | -49.27% |
| 2020 Q4 | 75.91 Million PLN | 10023.13% |
| 2020 FY | 73.7 Million PLN | 1627.07% |
| 2020 Q1 | -936.81 Thousand PLN | 35.26% |
| 2019 Q1 | -1.44 Million PLN | 41.78% |
| 2019 Q4 | -1.44 Million PLN | -45.21% |
| 2019 Q3 | -996.46 Thousand PLN | -6.27% |
| 2019 Q2 | -937.7 Thousand PLN | 35.12% |
| 2019 FY | -4.82 Million PLN | 5.74% |
| 2018 Q4 | -2.48 Million PLN | -160.07% |
| 2018 Q2 | -1.55 Million PLN | -164.65% |
| 2018 Q1 | -588.24 Thousand PLN | 63.57% |
| 2018 FY | -5.12 Million PLN | -98.77% |
| 2018 Q3 | -954.54 Thousand PLN | 38.68% |
| 2017 Q1 | -475.73 Thousand PLN | 73.04% |
| 2017 Q4 | -1.61 Million PLN | -1297.4% |
| 2017 FY | -2.57 Million PLN | -2.05% |
| 2017 Q3 | -115.54 Thousand PLN | 68.8% |
| 2017 Q2 | -370.27 Thousand PLN | 22.17% |
| 2016 Q3 | -58.08 Thousand PLN | 83.44% |
| 2016 Q4 | -1.76 Million PLN | -2938.3% |
| 2016 FY | -2.52 Million PLN | -218.16% |
| 2016 Q1 | -350.8 Thousand PLN | 0.0% |
| 2016 Q2 | -350.8 Thousand PLN | 0.0% |
| 2015 FY | -793.45 Thousand PLN | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioceltix S.A. | -15.81 Million PLN | -39.724% |
| BIOTON S.A. | 15.29 Million PLN | 244.516% |
| Captor Therapeutics Spolka Akcyjna | -73.01 Million PLN | 69.728% |
| Mabion S.A. | 55.06 Million PLN | 140.144% |
| NanoGroup S.A. | -7.9 Million PLN | -179.726% |
| Pharmena S.A. | 34.87 Million PLN | 163.387% |
| Poltreg S.A. | -16.86 Million PLN | -31.086% |
| Pure Biologics Spólka Akcyjna | -31.71 Million PLN | 30.312% |
| Ryvu Therapeutics S.A. | -100.94 Million PLN | 78.104% |
| Synthaverse S.A. | 8.64 Million PLN | 355.623% |
| Urteste S.A. | -6.44 Million PLN | -242.853% |